Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
In a world rife with complex global challenges, the need for innovative solutions to problems of development has never been greater. While we laud global efforts to eradicate extreme poverty, an ...
An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy studies may prove ...
The 25 number became popular off the back of brain imaging studies from the late 1990s and early 2000s. These studies often tracked changes through childhood and adolescence and showed that the brain ...
A blog by IDS alum and Chevening scholar Joydeep Sinha Roy, the Country Director of BRAC Tanzania, who studied at IDS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results